OSA patients with neuropsychiatric symptoms, such as depression, fatigue, sleepiness, headache, and memory impairment, had higher LC3B/ATG5 expression and lower DNA methylation levels over the promoter regions of these two genes. This evidence concerns the gene MAP1LC3B and depressive disorder.